Blocking inhibition to YAP by ActinomycinD enhances anti-tumor efficacy of Corosolic acid in treating liver cancer

Cellular Signalling

Volumn 29, Issue , 2017, Pages 209-217

  Xu, Yanfeng ^a   Zhao, Yinghui ^b   Xu, Yanli ^c   Guan, Yu ^a   Zhang, Xiao ^b   Chen, Yan ^b   Wu, Qi ^b   Zhu, Guoqing ^b   Chen, Yuxin ^b   Sun, Fenyong ^b   Wang, Jiayi ^b,d   Yu, Yongchun ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Dongjing Town Community Health Service Center of Songjiang District   (China)

^d TONGJI UNIVERSITY   (China)

Author keywords

Chemotherapy; Protein stability; Transformative phenotypes; YAP; TrCP

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BETATRCP; COROSOLIC ACID; DACTINOMYCIN; FORSKOLIN; KINASE LATS1; ONCOPROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; LATS1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRITERPENE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL TRANSFORMATION; COMBINATION DRUG THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; IC50; LIVER CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; HUMAN; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DACTINOMYCIN; DOWN-REGULATION; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MICE, NUDE; MODELS, BIOLOGICAL; PHENOTYPE; PHOSPHOPROTEINS; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; TRITERPENES; UBIQUITINATION;

EID: 84995427092     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.11.001     Document Type: Article

References (44)

1. [1] Hashim, D., Boffetta, P., La Vecchia, C., Rota, M., Bertuccio, P., Malvezzi, M., Negri, E., The global decrease in cancer mortality: trends and disparities. Ann. Oncol. 27 (2016), 926–933.
2. [2] Torre, L.A., Siegel, R.L., Ward, E.M., Jemal, A., Global Cancer Incidence and Mortality Rates and Trends–An Update. Cancer Epidemiol. Biomark. Prev. 25 (2016), 16–27.
3. [3] Watanabe, K., Current chemotherapeutic approaches for hepatoblastoma. Int. J. Clin. Oncol. 18 (2013), 955–961.
4. [4] Wu, F., Li, H., Jin, L., Li, X., Ma, Y., You, J., Li, S., Xu, Y., Deer antler base as a traditional Chinese medicine: a review of its traditional uses, chemistry and pharmacology. J. Ethnopharmacol. 145 (2013), 403–415.
5. [5] Jiang, M., Yang, J., Zhang, C., Liu, B., Chan, K., Cao, H., Liu, A., Clinical studies with traditional Chinese medicine in the past decade and future research and development. Planta Med. 76 (2010), 2048–2064.
6. [6] Zheng, G.Y., Xin, H.L., Li, B., Xu, Y.F., Yi, T.J., Ling, C.Q., Total saponin from root of Actinidia valvata Dunn prevents the metastasis of human hepatocellular carcinoma cells. Chin. J. Integr. Med. 18 (2012), 197–220.
7. [7] Kim, J.H., Kim, Y.H., Song, G.Y., Kim, D.E., Jeong, Y.J., Liu, K.H., Chung, Y.H., Oh, S., Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of β-catenin degradation. Food Chem. Toxicol. 67 (2014), 87–95.
8. [8] Horlad, H., Fujiwara, Y., Takemura, K., Ohnishi, K., Ikeda, T., Tsukamoto, H., Mizuta, H., Nishimura, Y., Takeya, M., Komohara, Y., Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells. Mol. Nutr. Food Res. 57 (2013), 1046–1054.
9. [9] Lee, H.S., Park, J.B., Lee, M.S., Cha, E.Y., Kim, J.Y., Sul, J.Y., Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin. Mol. Med. Rep. 12 (2015), 4782–4788.
10. [10] Xu, Y.F., Ge, R.L., Du, J., Xin, H.L., Yi, T.J., Sheng, J.Y., Wang, Y.Z., Ling, C.Q., Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells. Cancer Lett. 284 (2009), 229–237.
11. [11] Oudhoff, M.J., Braam, M.J., Freeman, S.A., Wong, D., Rattray, D.G., Wang, J., Antignano, F., Snyder, K., Refaeli, I., Hughes, M.R., McNagny, K.M., Gold, M.R., Arrowsmith, C.H., Sato, T., Rossi, F.M., Tatlock, J.H., Owen, D.R., Brown, P.J., Zaph, C., SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling. Dev. Cell 37 (2016), 47–57.
12. [12] Wang, J.Y., Ma, L.F., Weng, W.H., Qiao, Y.X., Zhang, Y., He, J.T., Wang, H.M., Xiao, W.F., Li, L., Chu, Q.H., Pan, Q.H., Yu, Y.C., Sun, F.Y., Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology 58 (2013), 1011–1020.
13. [13] Tang, X., Chen, X., Xu, Y., Qiao, Y.X., Zhang, X., Wang, Y.L., Guan, Y., Sun, F.Y., Wang, J.Y., CD166 positively regulates MCAM via inhibition to ubiquitin E3 ligases Smurf1 and βTrCP through PI3K/AKT and c-Raf/MEK/ERK signaling in Bel-7402 hepatocellular carcinoma cells. Cell. Signal. 27 (2015), 1694–1702.
14. [14] Wang, J.Y., Zhang, Y., Weng, W.H., Qiao, Y.X., Ma, L.F., Xiao, W.F., Yu, Y.C., Pan, Q.H., Sun, F.Y., Impaired phosphorylation and ubiquitination by p70 S6 kinase (p70S6K) and Smad ubiquitination regulatory factor 1 (Smurf1) promote tribbles homolog 2 (TRIB2) stability and carcinogenic property in liver cancer. J. Biol. Chem. 288 (2013), 33667–33681.
15. [15] Qiao, Y.X., Zhang, X., Zhang, Y., Wang, Y.L., Xu, Y.F., Liu, X.F., Sun, F.Y., Wang, J.Y., High glucose stimulates tumorigenesis in hepatocellular carcinoma (HCC) cells through AGER-dependent O-GlcNAcylation of c-Jun. Diabetes 65 (2016), 619–632.
16. [16] Kleeff, J., Kornmann, M., Sawhney, H., Korc, M., Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int. J. Cancer 86 (2000), 399–407.
17. [17] Szychot, E., Apps, J., Pritchard-Jones, K., Wilms' tumor: biology, diagnosis and treatment. Transl. Pediatr. 3 (2014), 12–24.
18. [18] Zhang, B.Z., Wang, K.R., Yan, J.X., Zhang, W., Song, J.J., Ni, J.M., Wang, R., In vitro and in vivo antitumor effects of novel actinomycin D analogs with amino acid substituted in the cyclic depsipeptides. Peptides 31 (2010), 568–573.
19. [19] Peng, M., Ding, Y., Yu, L., Deng, Y., Lai, W., Hu, Y., Zhang, H., Wu, X., Fan, H., Ding, H., Wu, Y., Tao, G., Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm. PLoS One, 10, 2015, e0143531.
20. [20] Wang, J.Y., Tang, X., Weng, W.H., Qiao, Y.X., Lin, J., Liu, W.W., Liu, R., Ma, L.F., Yu, W.J., Yu, Y.C., Pan, Q.H., Sun, F.Y., The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma. Oncogene 34 (2015), 5781–5795.
21. [21] Xu, S.S., Tong, M.H., Huang, J.Q., Zhang, Y., Qiao, Y.X., Weng, W.H., Liu, W.W., Wang, J.Y., Sun, F.Y., TRIB2 inhibits Wnt/b-Catenin/TCF4 signaling through its associated ubiquitin E3 ligases, b-TrCP, COP1 and Smurf1, in liver cancer cells. FEBS Lett. 588 (2014), 4334–4341.
22. [22] Wang, J.Y., Wang, H.M., Zhang, Y., Zhen, N., Zhang, L., Qiao, Y.X., Weng, W.H., Liu, X.F., Ma, L.F., Xiao, W.F., Yu, W.J., Chu, Q.H., Pan, Q.H., Sun, F.Y., Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. Cell. Signal. 26 (2014), 1048–1059.
23. [23] Mommer, L., Wagemaker, C.A., Kroon, H.D.E., Ouborg, N.J., Unravelling below-ground plant distributions: a real-time polymerase chain reaction method for quantifying species proportions in mixed root samples. Mol. Ecol. Resour. 8 (2008), 947–953.
24. [24] Wang, J.Y., Park, J.S., Wei, Y., Rajurkar, M., Cotton, J.L., Fan, Q., Lewis, B.C., Ji, H., Mao, J., TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function. Mol. Cell 51 (2013), 211–225.
25. [25] Yu, W.J., Qiao, Y.X., Tang, X., Ma, L.F., Wang, Y.L., Zhang, X., Weng, W.H., Pan, Q.H., Yu, Y.C., Sun, F.Y., Wang, J.Y., Tumor suppressor long non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells. Cell. Signal. 26 (2014), 2961–2968.
26. [26] Xu, M.Z., Yao, T.J., Lee, N.P.Y., Ng, I.O.L., Chan, Y.T., Zender, L., Lowe, S.W., Poon, R.T.P., Luk, J.M., Yes-Associated Protein Is an Independent Prognostic Marker in Hepatocellular Carcinoma. Cancer 19 (2009), 4576–4585.
27. [27] Zhao, B., Li, L., Tumaneng, K., Wang, C.Y., Guan, K.L., A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 24 (2010), 72–85.
28. [28] Moleirinho, S., Chang, N., Sims, A.H., Tilston-Lünel, A.M., Angus, L., Steele, A., Boswell, V., Barnett, S.C., Ormandy, C., Faratian, D., Gunn-Moore, F.J., Reynolds, P.A., KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals. Oncogene 14 (2013), 1821–1830.
29. [29] Shukla, S., Allam, U.S., Ahsan, A., Chen, G., Krishnamurthy, P.M., Marsh, K., Rumschlag, M., Shankar, S., Whitehead, C., Schipper, M., Basrur, V., Southworth, D.R., Chinnaiyan, A.M., Rehemtulla, A., Beer, D.G., Lawrence, T.S., Nyati, M.K., Ray, D., KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. Neoplasia 2 (2014), 115–128.
30. [30] Piccolo, S., Dupont, S., Cordenonsi, M., The biology of YAP/TAZ: hippo signaling and beyond. Physiol. Rev. 94 (2014), 1287–1312.
31. [31] Pobbati, A.V., Han, X., Hung, A.W., Huda, N., Chen, G.Y., Kang, C., Chia, C.S., Luo, X., Hong, W., A Poulsen, Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure 23 (2015), 2076–2086.
32. [32] Qiao, Y., Lin, S.J., Chen, Y., Voon, D.C., Zhu, F., Chuang, L.S., Wang, T., Tan, P., Lee, S.C., Yeoh, K.G., Sudol, M., Ito, Y., RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cance. Oncogene 35 (2016), 2664–2674.
33. [33] Azzolin, L., Panciera, T., Soligo, S., Enzo, E., Bicciato, S., Dupont, S., Bresolin, S., Frasson, C., Basso, G., Guzzardo, V., Fassina, A., Cordenonsi, M., Piccolo, S., YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 158 (2014), 157–170.
34. [34] Lapi, E., Di Agostino, S., Donzelli, S., Gal, H., Domany, E., Rechavi, G., Pandolfi, P.P., Givol, D., Strano, S., Lu, X., Blandino, G., PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol. Cell 32 (2008), 803–814.
35. [35] Chen, D., Liu, S., Zhang, W., Sun, L., Rational design of YAP WW1 domain-binding peptides to target TGFβ/BMP/Smad-YAP interaction in heterotopic ossification. J. Pept. Sci. 21 (2015), 826–832.
36. [36] Vigneron, A.M., Ludwig, R.L., Vousden, K.H., Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev. 24 (2010), 2430–2439.
37. [37] Ma, K., Xu, Q., Wang, S., Zhang, W., Liu, M., Liang, S., Zhu, H., Xu, N., Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. Cancer Lett. 375 (2016), 84–91.
38. [38] Richlya, H., Schultheisb, B., Adamietzc, I.A., Kupscha, P., Gruberta, M., Hilgera, R.A., Ludwigd, M., Brendeld, E., Christensene, O., Strumberg, D., Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial. Eur. J. Cancer 45 (2009), 579–587.
39. [39] Guo, L., Fan, L., Ren, J., Pang, Z., Ren, Y., Li, J., Wen, Z., Qian, Y., Zhang, L., Ma, H., Jiang, X., Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int. J. Nanomedicine 7 (2012), 1449–1460.
40. [40] Wang, M.J., Liu, S., Liu, Y., Zheng, D., Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells. Neurosci. Res. 59 (2007), 40–46.
41. [41] Ferrari, S., Palmerini, E., Alberghini, M., Staals, E., Mercuri, M., Barbieri, E., Longhi, A., Cantero, L., Cesari, M., Abate, M., Balladelli, A., Picci, P., Bacci, G., Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study. Tumori 96 (2010), 213–218.
42. [42] Chen, Y., Liu, J., Yuan, B., Cao, C., Qin, S., Cao, X., Bian, G., Wang, Z., Jiang, J., Methylated actinomycin D, a novel actinomycin D analog induces apoptosis in HepG2 cells through Fas- and mitochondria-mediated pathways. Mol. Carcinog. 52 (2013), 983–996.
43. [43] Qu, L., Zhang, H., Yang, Y., Yang, G., Xin, H., Ling, C., Corosolic acid analogue, a natural triterpenoid saponin, induces apoptosis on human hepatocarcinoma cells through mitochondrial pathway in vitro. Pharm. Biol. 25 (2016), 1–13.
44. [44] Kimura, T.E., Duggirala, A., Smith, M.C., White, S., Sala-Newby, G.B., Newby, A.C., Bond, M., The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP. J. Mol. Cell. Cardiol. 90 (2016), 1–10.